Clearmind Medicine Completes Enrollment for First Cohort in Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Inc. has announced the successful enrollment of the last patient for the first cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100, a proprietary MEAI-based oral drug candidate aimed at treating Alcohol Use Disorder (AUD). The trial, which is being conducted at Johns Hopkins University School of Medicine and Yale School of Medicine’s Department of Psychiatry, has enrolled six patients to date. This multinational, multicenter study is designed to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also exploring preliminary efficacy signals such as reductions in alcohol cravings and consumption. The trial represents a critical step in advancing CMND-100 as a potential innovative therapy for AUD, a condition where current treatments often fall short. Clearmind Medicine is committed to delivering safe and effective solutions for the underserved AUD community and looks forward to sharing topline data from the first cohort.